Trials / Unknown
UnknownNCT05801146
Evaluate the Safety and Efficacy of HG102 as Compared to Botox® in Subject With Moderate to Severe Glabellar Lines
A Double-blind, Randomized, Parallel, Active-controlled, Non-inferiority, Phase III Clinical Trial to Compare the Efficacy and Safety of HG102 Versus Botox® in Subjects With Moderate to Severe Glabellar Lines
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 272 (estimated)
- Sponsor
- Hugel · Industry
- Sex
- All
- Age
- 19 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the efficacy and safety of HG102 for moderate to severe Glabellar Lines, non-inferiority compared to Botox® was confirmed and safety was evaluated.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Botulinum Toxin Type A Injection [HG102] | Single administration, Day 0, 20 units |
| DRUG | Botulinum Toxin Type A Injection [Botox] | Single administration, Day 0, 20 units |
Timeline
- Start date
- 2024-01-04
- Primary completion
- 2025-03-01
- Completion
- 2025-10-01
- First posted
- 2023-04-06
- Last updated
- 2024-01-16
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT05801146. Inclusion in this directory is not an endorsement.